Silas_Guerra Posted - 17 hours ago

🚨 MYNZ Petra Brand Ambassador says to keep an eye on "BIG NEWS from the NFL." This is going to run parabolic soon, right after the healthcare giant Thermo Fisher ($210B mkt cap) partnered with Mainz to develop and launch together ColoAlert in US 🚀 Buy the dip now, the train is leaving very soon. $NAMS $OCUL $KNSA

Mae_Edwards Posted - 17 hours ago

🚨 MYNZ Petra Brand Ambassador says to keep an eye on "BIG NEWS from the NFL." This is going to run parabolic soon, right after the healthcare giant Thermo Fisher ($210B mkt cap) partnered with Mainz to develop and launch together ColoAlert in US 🚀 Buy the dip now, the train is leaving very soon. $KNSA $DAWN $SPRY

Luka_Law Posted - 2 days ago

$KNSA $DAWN LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

clownmarket Posted - 1 week ago

$BCRX $TGTX $KNSA $IOVA $ARDX Time for this again! Everyone's reported I can only tag 5 tickers btw There were impressive quarters from a few companies in Q3, notably Briumvi, Arcalyst and Orladeyo outperformed. Xphao---whatever also had a great Q but that was overshadowed by the CMS drama IOVA's drug was requested and I put it on, but I'm not sure how to show it - they report with "proleukin" revenues bundled but this is meant to be a single drug's performance. I may remove proleukin unless it's truly part of the same thing. I'm not sure - what do you think? Note that Ibsrela's performance is EXACTLY the same as Lupkynis for the last few Qs Also note that this is top line revenue and some of these drugs come with much lower margins than others

PenkeTrading Posted - 2 weeks ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Kiniksa Pharmaceuticals Ltd. Is that bullish or bearish? $KNSA #Kiniksa #RsiOversold #NASDAQ

Fastcapital Posted - 2 weeks ago

$CRDL Part 2: If you look at my last post, how can doctors prescribe $KNSA’s rilonacept—a drug that is this unsafe, with so many side effects and an incredibly high cost of $250,000 per year, generating $400 million in revenue in 2024 in the U.S. alone? On average, patients need to be on this drug for 27 months. It’s crazy for an immunosuppressive! Plus, you have to take monthly injections, while $CRDL’s CardiolRX offers a safer alternative with almost no side effects, at a cost of only $50,000 per year—1/5 the price of rilonacept. CardiolRX achieves the same results and reduction in inflammation and can be taken with water, which many patients prefer. Cardiol is also entering the U.S. and European markets. Put all this together, and it’s a no-brainer.

Fastcapital Posted - 2 weeks ago

$crdl Part 1: Investors will see when it's too late. Cardiol is on the verge of a winner medicine. Very safe drug, interim results shown incredible results chest pain went down 63% that's are the same results as the only FDA approved medicine Rilonacept (this is an immunosuppresive). Inflammation went down 95% this all within 8 weeks! Immunosuppressive drugs lead to significant side effects. The average you have to be on Rilonacept is 27 months. Check the last press release from $KNSA with the quarterly results that's terrible for patients. "As of the end of the third quarter of 2024, average total duration of ARCALYST therapy in recurrent pericarditis increased to approximately 27 months." CardiolRX: 63% less chest pain within 8 weeks. 95% less inflammation within 8 weeks. Safe Drug. Taken with water. $50.000 price. Rilonacept: 67% less pain within 8 weeks. 94% less inflammation within 8 weeks. Unsafe drug (immunosuppresive) 27 months on average. Taken with injection. $250.000 price.

Quantumup Posted - 10/30/24

Evercore ISI raised the price target on $KNSA to $35 was $30/Outperform, says "We recommend buying KNSA on weakness as the stock traded down post earnings, reaching 9% 3Q growth (vs 33% in 2Q), which was unusually high due to a few one-time factors in 2Q (lower gross to net and higher compliance):"

LewisDaKat Posted - 10/29/24

$KNSA News Article Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution https://marketwirenews.com/news-releases/kiniksa-pharmaceuticals-reports-third-quarter-2024-f-6598214473056053.html $KNSA

StreetwiseReports Posted - 10/29/24

Mass. Biotech Shares Strong Q3 Results: https://ow.ly/lYha50TVRrI Kiniksa Pharmaceuticals Ltd. recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note. $KNSA #pharmastocks

buy_undervalued_stocks Posted - 10/29/24

$KNSA NO PROFITS!!! Keep raising revenue guidance, keep losing more money... Idiot management team...

sunset_PARK Posted - 10/29/24

$KNSA wondering what they will bring in in q4 since they lost around 40m in firts 3 q but maintain cash flow positive guidance on an annual basis?

Happy_Feet19 Posted - 10/29/24

$KNSA Why the Decline in Price? Earnings reports looks great!

HaltTradeAlert Posted - 10/29/24

$KNSA Halt Time: 09:33:41 Issue Symbol: KNSA Reason Code: LUDP Last Price: $23.45 Volume: 57.4 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

RonIsWrong Posted - 10/29/24

$KNSA – ARCALYST ® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – [note: Compared To Prior Guidance Of $405M-$415M] – Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY ® Award-winning singer-songwriter, Carly Pearce – – Kiniksa expects to remain cash flow positive on an annual basis –

Doozio Posted - 10/28/24

$KNSA da huckleberries are at da $$$$ in da FUTUre of 🧠⏰ which is NOW during 🧠⏰♾️

RonIsWrong Posted - 10/28/24

$KNSA there it is. 🍪🍪

RonIsWrong Posted - 10/25/24

$KNSA 👀

RonIsWrong Posted - 10/25/24

$KNSA cookies

NJgolfer Posted - 1 month ago

$KNSA 13 week, 17% base. Looks like a high flag pattern after breakout back in July. Worked off overbought weekly MACD and just posted positive Chaikin money flow today. Upside targets of $31 and $34 for an intermediate term trade. $40 for longer term target. Added to buy list

ChartsNbulls Posted - 1 month ago

@Rbyild you knew about this new study that was announced this morning???? This new study being run with the phase 3 is directly taking $KNSA patients who could for whatever reason not take their pericarditis drug and show they can use cardiol rx without all the side effects, $KNSA has a 2b market cap !! Crdl will be doing an extra study on top of the phase 3 to prove their drug is superior, this explains the raise and who the hell would put millions into a new study you didn’t budget for unless you thought you will get favorable outcomes. The vast majority DONT understand this news release.

Fastcapital Posted - 1 month ago

$CRDL a lot of people forget that $CRDL can go to the US and Europe and other parts of the world with their $50.000 price for the CardiolRX drug. $KNSA Kiniksa can only go to the US with their $250.000 price for the drug

ChartsNbulls Posted - 1 month ago

@PDM21 reading through other sites it appears that this study could be fully concluded within 6months give or take. This could effectively take $KNSA out of the pericarditis game all together, and $CRDL has ODD as a bonus.

ChartsNbulls Posted - 1 month ago

$KNSA if I’m understanding the news from $CRDL correctly, this could be very interesting, $CRDL will run a study on patients using $KNSA block buster pericarditis drug who could not handle the side effects and show they can safely use $CRDL at a fraction of the price and NO serious side effects and their phase 2 showed same outcomes of $KNSA minus the dangerous immune suppression and other side effects. Going to be very interesting!

Stocktud Posted - 1 month ago

$CRDL $KNSA anyone plan to buyout Crdl? 5-13 billions market

Fastcapital Posted - 1 month ago

$CRDL Huge news today from Cardiol Therapeutics. It shows the competitor $KNSA with their medicine rilonacept for Recurrent pericarditis. Is super expensive $250.000 a year. Has a lot of side effects, needs to be injected more times a month. Is a Immune suppresive. Has the same effectiveness as CardiolRX. Rilonacept also has a growing body of evidence indicating pericarditis recurrence rates are as high as seventy-five percent and onset is rapid following cessation of IL-1 blocker therapy. Cardiol does a side trial that will indicate that CardiolRX is a better option testing Rilonacept patients that quit or didn't see effects from this medicine. CardiolRX costs $50.000 a year. minimal side effects. is taken with water. CBD molecule medicine so means not dangerous for the body. Same effectiveness as Rilonacept. That the competitor has a 75% relapse or recurrence after quitting the medicine only show why a medicine like CardiolRX is a must needed medicine for Pericarditis patients.

Fastcapital Posted - 1 month ago

$CRDL Summary Cardiol Announcement Cardiol Therapeutics Inc. is advancing CardiolRx™ into late-stage clinical research with the MAVERIC-2 study, targeting recurrent pericarditis after stopping interleukin-1 (IL-1) blocker therapy, specifically rilonacept and anakinra. The trial will start in Q4 2024 at major centers in the U.S. and Europe, running alongside the planned Phase III program (MAVERIC-3). Key Details of MAVERIC-2: Target Group: Approximately 110 patients currently receiving IL-1 blocker therapy. Design: Randomized, double-blind, placebo-controlled trial comparing CardiolRx™ with placebo after stopping IL-1 blockers. Goal: Evaluate CardiolRx™ effectiveness in preventing new episodes of recurrent pericarditis. CardiolRx™ inhibits the NLRP3 inflammasome, potentially providing a more effective treatment for patients intolerant to existing therapies. Kiniksa Pharmaceuticals, parent of rilonacept High recurrence rates (up to 75%) ($KNSA), has a market cap of $1.84 billion.

RonIsWrong Posted - 1 month ago

$KNSA From A Wells Fargo Weekly Update: We held our Therapeutics KOL forum this week and walked away with insights galore [Here's what they had about KNSA] - Docs believe Arcalyst can become SOC in recurrent pericarditis; - KOLs expect Arcalyst treatment duration to be ~12 months; - Payers are approving Arcalyst for ~12-18 months. Courtesy of @DonCorleone77

insiderbuyingselling Posted - 1 month ago

$KNSA new insider selling: 17000 shares. http://insiderbuyingselling.com/?t=KNSA

RonIsWrong Posted - 1 month ago

$KNSA 👀 may get interesting here again